New Delhi: A pan India study carried out has shown that two doses of Covisheld Covid-19 Vaccine is producing more antibodies than two doses of Covaxin. The study, which is yet to be reviewed and shared in medRxiv, was carried out among healthcare workers in the country. Samples of 515 healthcare workers from 22 cities were taken for the study. The study showed both the vaccines Covishield and Covaxin gave promising results of immune response after two doses.
According to the study, of the 425 Covishield and 90 Covaxin recipients, 98.1 per cent and 80 per cent, respectively, showed seropositivity which means Covishield triggered more antibodies than Covaxin. Seropositivity rates and median anti-spike antibody titre were higher in the Covishield arm when compared to the Covaxin arm. The study also reveals that both the seropositivity rate and the average rise in anti-spike antibody were significantly higher in Covishield versus Covaxin recipients. The study also indicated good safety profile for both vaccines and both are effective.
Comments are closed.